Previous 10 | Next 10 |
KalVista Pharmaceuticals ( NASDAQ: KALV ) is selling common shares and warrants to institutional investors in a registered direct offering to raise gross proceeds of ~$58M. The company is selling ~9.48M common shares at $6 per share and 182.47K prefunded warrants at $5.999 fo...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it has entered into a subscription agreement with institutional investors to sel...
KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q2 GAAP EPS of -$0.90 beats by $0.16 . Cash, cash equivalents and marketable securities were $122.3 million as of October 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketa...
– Results show the impact of attacks on mental health, daily activities, and quality of life in people living with HAE - – Real-world data demonstrate treatment burden associated with on-demand parenteral HAE therapies - KalVista Pharmaceuticals, Inc. (...
KalVista Pharmaceuticals ( NASDAQ: KALV ) on Monday reported data from a phase 1 trial of an orally disintegrating tablet (ODT) formulation of its drug sebetralstat. Sebetralstat is currently being developed in a phase 3 trial called KONFIDENT as a therapy for hereditary...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulatio...
- The discovery and optimization of sebetralstat published in the Journal of Medicinal Chemistry - - Data on absorption, metabolism, and excretion of sebetralstat reported in the journal Xenobiotica - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical ...
KalVista Pharmaceuticals ( NASDAQ: KALV ) has appointed current Board member Brian J.G. Pereira, M.D, as Chairman, effective immediately succeeding Martin Edwards, MD, who has resigned from the Board in a planned transition. For further detai...
– Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibit...
Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the s...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...